Our first product to market is Short™ AE-IGF-1, a well-characterized, high potency, competitively priced alternative to insulin and other insulin-like analogues.
CellRx also offers a range of specialist services to the bioprocessing industry including GMP contract manufacturing, bioprocess development and optimization.
CellRx Short AE-IGF-1 is available for laboratory research and large-scale in-vitro biopharmaceutical manufacturing use only. Not for diagnostic or therapeutic use.
Short™AE-IGF-1 is a registered trademark of CellRx Limited.